Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2005

View Archived Issues

DA-8159 as a treatment for diabetic erectile dysfunction

CC-4047's mechanism of action remains unclear

NexBio presents Fludase, a novel antiinfluenza recombinant fusion protein / News in Context

Two liposomal lurtotecan regimens induce antitumor effects in relapsed ovarian cancer

CEP-8983 chemosensitizes resistant cells and xenografts

BTS-2 inhibitory activity depends on redox state of tNOX

APF-530 enters phase II for CINV in cancer patients

ISTA seeks green light for phase III trial of combination ophthalmic product

ZLB Behring to study C1-INH concentrate for hereditary angioedema

Inspire reports ophthalmic programs update

Mitsubishi Chemical and Mitsubishi Pharma to form joint holding company

Phase I cancer study of CYT-997 set to begin in May

Prism to market Penwest's PW-2101 in U.S., Canada

Vical's bivalent CMV vaccine set for phase II

ISIS-369645 enters development for asthma

New treatments for cancer covered in recent patents

AS-1410 selected for phase I evaluation against cancer

Complete tumor regression in mice treated with huC242-DM4

First, highly selective 5-HT1D antagonist reported

Novel antihypertensive agents discovered at Bristol-Myers Squibb

Santarus reports new formulations of omeprazole for treating acid-induced gastrointestinal disorders

New antidiabetic agents from Ligand and Takeda

Phase I data confirm MVA-3000 vaccine is safe and immunogenic in healthy volunteers

Evidence suggests a link between sleep disorders and metabolic syndrome in mice

UNBS-1450 demonstrates in vitro and in vivo anticancer activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...